{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:50:23Z","timestamp":1760550623579,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA21661","U10 CA37422"],"award-info":[{"award-number":["U10 CA21661","U10 CA37422"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12149-018-1278-4","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T04:30:55Z","timestamp":1533789055000},"page":"553-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial"],"prefix":"10.1007","volume":"32","author":[{"name":"for the NRG Oncology","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Seider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Demas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Rashtian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy L.","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome David","family":"Derdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean F.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tomblyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"Rabinovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Kachnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence B.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"key":"1278_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584\u201393.","journal-title":"Nat Rev Cancer"},{"key":"1278_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61\u20136.","journal-title":"Br J Cancer"},{"key":"1278_CR3","first-page":"84","volume":"8","author":"HH Yu","year":"2012","unstructured":"Yu HH, Tsai YY, et al. Overview of diagnosis and management of metastatic disease to bone. Cancer Control. 2012;8:84\u201391.","journal-title":"Cancer Control"},{"key":"1278_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/107327481201900210","volume":"8","author":"S Buga","year":"2012","unstructured":"Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control. 2012;8:154\u201366.","journal-title":"Cancer Control"},{"issue":"16","key":"1278_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655\u201364.","journal-title":"N Engl J Med"},{"key":"1278_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","volume":"27","author":"KM Bussard","year":"2008","unstructured":"Bussard KM, Gay CV, et al. The bone microenvironment in metastasis: what is special about bone? Cancer Metastasis Rev. 2008;27:41\u201355.","journal-title":"Cancer Metastasis Rev"},{"key":"1278_CR7","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. J Clin Oncol. 2010;28:5132\u20139.","journal-title":"J Clin Oncol"},{"key":"1278_CR8","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1200\/JCO.2013.50.1502","volume":"31","author":"HJ West","year":"2013","unstructured":"West HJ. Patients with advanced non\u2013small-cell lung cancer and marginal performance status: walking the tight rope towards improved survival. J Clin Oncol. 2013;31:2841\u20133.","journal-title":"J Clin Oncol"},{"key":"1278_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","volume":"27","author":"M Zelen","year":"1974","unstructured":"Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 1974;27:365\u201375.","journal-title":"J Chron Dis"},{"issue":"23","key":"1278_CR10","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","volume":"21","author":"EJ Small","year":"2003","unstructured":"Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277\u201384.","journal-title":"J Clin Oncol"},{"key":"1278_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","volume":"89","author":"SM Domcheck","year":"2000","unstructured":"Domcheck SM, Younger J, Finkelstein DM, et al. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 2000;89:363\u20138.","journal-title":"Cancer"},{"issue":"16","key":"1278_CR12","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian R, Hirsh V, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: phase III, double blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150\u20137.","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"1278_CR13","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(Suppl 8):1588\u201394.","journal-title":"Cancer"},{"key":"1278_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/00006231-199609000-00011","volume":"17","author":"R Sciuto","year":"1996","unstructured":"Sciuto R, Festa A, et al. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996;17:799\u2013804.","journal-title":"Nucl Med Commun"},{"key":"1278_CR15","first-page":"79","volume":"43","author":"R Sciuto","year":"2002","unstructured":"Sciuto R, Festa A, et al. Effects of low dose cisplatin on 89Sr therapy for painful bony metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79\u201386.","journal-title":"J Nucl Med"},{"key":"1278_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","volume":"357","author":"SM Tu","year":"2001","unstructured":"Tu SM, Millikan RE, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336\u201341.","journal-title":"Lancet"},{"key":"1278_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","volume":"44","author":"GO Oosterhof","year":"2003","unstructured":"Oosterhof GO, Roberts JT, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organization for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44:519\u201326.","journal-title":"Eur Urol"},{"key":"1278_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","volume":"31","author":"PM Quilty","year":"1994","unstructured":"Quilty PM, Kirk D, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33\u201340.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1278_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, ALSYMPCA Investigators, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"1278_CR20","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.2008.20.4164","volume":"27","author":"MJ Morris","year":"2009","unstructured":"Morris MJ, Pandit-Taskar N, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:2436\u201342.","journal-title":"J Clin Oncol"},{"key":"1278_CR21","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1200\/JCO.2008.20.5393","volume":"27","author":"SM Tu","year":"2009","unstructured":"Tu SM, Mathew P, et al. Phase I study of concurrent weekly Docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:3319\u201324.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1278_CR22","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Beuzeboc P, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27(15):2429\u201335.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-018-1278-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:48:57Z","timestamp":1589449737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-018-1278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1278-4","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"type":"print","value":"0914-7187"},{"type":"electronic","value":"1864-6433"}],"subject":[],"published":{"date-parts":[[2018,8,9]]},"assertion":[{"value":"7 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}